Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 901–1,000 of 1,017
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 45
Bond, C., & Whitehall, V. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/9250757 · Cited by 54
Zhang, H., Liu, R., Yan, C., Liu, L., Tong, Z., Jiang, W., Yao, M., Fang, W. J., & Chen, Z. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.015 · Cited by 45
Human T cell glycosylation and implications on immune therapy for cancer
Bousser, E. D., Meuris, L., Callewaert, N., & Festjens, N. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1730658 · Cited by 52
Genetic and Epigenetic Biomarkers of Colorectal Cancer
Choong, M. K., & Tsafnat, G. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.020 · Cited by 55
Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 51
“etuximab (a chimeric anti-EGFR monoclonal antibody) as been shown to be effective in both first-line [164,165] nd chemotherapy refractory settings [166,167] while pantumumab (a fully humanised monoclonal antibody) has emonstrated efficacy in the chemotherapy-refractory setting 168] with preliminary results reported in…”
BackgroundTherapeutic modulation of k-ras signaling in colorectal cancer
Krens, L. L., Baas, J. M., Gelderblom, H. A. J., & Guchelaar, H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.012 · Cited by 53
Guérin, E., Raffelsberger, W., Pencreach, E., Maier, A., Neuville, A., Schneider, A., Bachellier, P., Rohr, S., Petitprez, A., Poch, O., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00120 · Cited by 44
Colorectal Cancer: Pathogenesis and Targeted Therapy
Li, J., Pan, J., Wang, L., Ji, G., & Dang, Y. (2025) · MedComm · doi:10.1002/mco2.70127 · Cited by 56
“The combination of FOLFOX or FOLFIRI regimens with cetuximab has proven effective in enhancing progression-free survival and objective response rates in CRC patients [201].”
Renal toxicity of anticancer agents targeting HER2 and EGFR
Cosmai, L., Gallieni, M. A., & Porta, C. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0226-9 · Cited by 45
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
Lee, C. S., Cragg, M. S., Glennie, M. J., & Johnson, P. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12164 · Cited by 46
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Bendell, J. C., Rosen, L. S., Mayer, R. J., Goldman, J. W., Infante, J. R., Benedetti, F. M., Lin, D., Mizuguchi, H., Zergebel, C., & Patel, M. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2850-4 · Cited by 46
Maus, M. K. H., Hanna, D. L., Stephens, C. L., Astrow, S. H., Yang, D., Grimminger, P., Loupakis, F., Hsiang, J., Zeger, G. D., Wakatsuki, T., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.73 · Cited by 47
Schlaeth, M., Berger, S., Derer, S., Klausz, K., Lohse, S., Dechant, M., Lazar, G. A., Schneider‐Merck, T., Peipp, M., & Valerius, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01505.x · Cited by 54
Trippett, T. M., Herzog, C. E., Whitlock, J. A., Wolff, J. E. A., Kuttesch, J. F., Bagatell, R., Hunger, S. P., Boklan, J., Smith, A., Arceci, R. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8975 · Cited by 46
Clinical Biomarkers in Oncology: Focus on Colorectal Cancer
Roock, W. D., Biesmans, B., Schutter, J. D., & Tejpar, S. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256319 · Cited by 52
Self-citationSaif, M. W., Kaley, K., Chu, E., & Copur, M. S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.046 · Cited by 47
Ulivi, P., Capelli, L., Valgiusti, M., Zoli, W., Scarpi, E., Chiadini, E., Rosetti, P., Bravaccini, S., Calistri, D., Saragoni, L., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-87 · Cited by 47
Kiyohara, Y., Yoshino, K., Kubota, S., Okuyama, H., Endo, H., Ueda, Y., Kimura, T., Kimura, T., Kamiura, S., & Inoue, M. (2016) · Cancer Science · doi:10.1111/cas.12898 · Cited by 45
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-32805-8_6 · Cited by 51
Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes
Sasaki, K., Margonis, G. A., Andreatos, N., Kim, Y., Wilson, A., Gani, F., Amini, N., & Pawlik, T. M. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.06.098 · Cited by 47
Hofheinz, R.-D., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.032 · Cited by 42
Huxley, N., Crathorne, L., Varley‐Campbell, J., Tikhonova, I. A., Snowsill, T., Briscoe, S., Peters, J., Bond, M. L., Napier, M., & Hoyle, M. (2017) · Health Technology Assessment · doi:10.3310/hta21380 · Cited by 48
Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis
Pulte, D. D., Jansen, L., & Brenner, H. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001068 · Cited by 47
Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review
Ribeiro, I. B., de Moura, D. T. H., Thompson, C. C., & de Moura, E. G. H. (2019) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v11.i3.193 · Cited by 45
Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?
Lee, H., & Cleynen, I. (2019) · Cells · doi:10.3390/cells8060535 · Cited by 50
“One of several examples in cancer treatment is cetuximab, for which the beneficial effects seem limited to patients with KRAS wild-type metastatic colorectal cancer [63].”
BackgroundGeldof, T., Popovic, D. D., Damme, N. V., Huys, I., & Dyck, W. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-57799-w · Cited by 47
Kim, D. W., Tan, E. S., Zhou, J., Schell, M. J., Martinez, M., Yu, J. B., Carballido, E. M., Mehta, R. J., Strosberg, J., Imanirad, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01368-z · Cited by 48
Cten Is Targeted by Kras Signalling to Regulate Cell Motility in the Colon and Pancreas
Alghamdi, S. A. A., Albasri, A. M., Cachat, J., Ibrahem, S., Muhammad, B. A., Jackson, D., Nateri, A. S., Kindle, K. B., & Ilyas, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020919 · Cited by 46
“The use of biologics targeted to the EGFR can have a dramatic effect on CRC resulting in marked reduction in tumour size and clinical down-staging [23].”
MethodRossini, D., Boccaccino, A., Carullo, M., Antoniotti, C., Dima, G., Ciracì, P., Marmorino, F., Moretto, R., Masi, G., & Cremolini, C. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.006 · Cited by 51
Nakadate, Y., Kodera, Y., Kitamura, Y., Shirasawa, S., Tachibana, T., Tamura, T., & Koizumi, F. (2014) · International Journal of Cancer · doi:10.1002/ijc.28550 · Cited by 43
“Several retrospective analyses have clearly demonstrated that activating mutations of KRAS confer resistance to cetuximab therapy in patients with mCRC.(5,19,20) Given the results of these analyses, the use of cetuximab has been restricted to mCRC patients with wild-type KRAS tumors.”
BackgroundBalschun, K., Haag, J., Wenke, A.-K., Schönfels, W. V., Schwarz, N. T., & Röcken, C. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.03.002 · Cited by 51
Nishiofuku, H., Tanaka, T., Matsuoka, M., Otsuji, T., Anai, H., Sueyoshi, S., Inaba, Y., Koyama, F., Sho, M., Nakajima, Y., et al. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.09.010 · Cited by 45
Ouwerkerk, J., & Boers-Doets, C. B. (2010) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2010.03.004 · Cited by 47
“Van Cutsem et al. (2007) Open-label, phase III Chemotherapy-refractory patients N1⁄4 463 Panitumumab 6 mg/m q2w and BSC (n1⁄4 231) vs BSC (n1⁄4 232) PFS: HR, 0.”
Seol, H. S., Kang, H.-J., Lee, S.-I., Kim, N. E., Kim, T., Chun, S., Kim, T. W., Yu, C. S., Suh, Y., Singh, S. R., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.010 · Cited by 43
Ishizuka, M., Nagata, H., Takagi, K., Iwasaki, Y., & Kubota, K. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2384-5 · Cited by 46
Biopsy for liver cancer: How to balance research needs with evidence‐based clinical practice
Sherman, M., & Bruix, J. (2014) · Hepatology · doi:10.1002/hep.27563 · Cited by 43
Miao, Z., Ren, G., Liu, H., Jiang, L., & Cheng, Z. (2010) · Journal of Biomedical Optics · doi:10.1117/1.3432738 · Cited by 44
Stefano, A. D., & Carlomagno, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 51
D’Angelo, D., Müssnich, P., Rosa, R., Bianco, R., Tortora, G., & Fusco, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-851 · Cited by 45
Proteomics as a guiding tool for more effective personalized therapy
Lee, J.-M., & Kohn, E. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq375 · Cited by 45
“Here, mutational activation of K-ras was shown to be a negative predictive biomarker for outcome [20, 21].”
BackgroundMolecular Testing in Colorectal Cancer
Shi, C., & Washington, K. M. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpi83dinulujni · Cited by 50
Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma.
Sanoff, H. K., Bernard, S. A., Goldberg, R. M., Morse, M. A., Garcia, R. A., Woods, L., Moore, D., & O’Neil, B. H. (2011) · PubMed Central · Cited by 43
Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients
Romiti, A., Raffa, S., Rocco, R. D., Roberto, M., Milano, A., Zullo, A., Leone, L., Ranieri, D., Mazzetta, F., Medda, E., et al. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.233.arom1 · Cited by 43
“However, overall survival (OS) of patients with advanced CRC has been improved by the combination of traditional anti-proliferative agents with newer targeted molecules, which inhibit signal transduction pathways [3, 4].”
BackgroundAkil, H., Perraud, A., Jauberteau, M., & Mathonnet, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.490 · Cited by 49
Lin, Y.-W., Raj, E. N., Liao, W., Lin, J., Liu, K., Chen, T.-H., Cheng, H.-C., Wang, C.-C., Li, L. Y., Chen, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09983-8 · Cited by 48
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
Kim, J. W., Cho, Y. B., & Lee, S. (2021) · Cells · doi:10.3390/cells10030670 · Cited by 45
“Furthermore, the W9 antibody could increase and restore sensitivity to v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors in BRAFV600E melanoma cells that have acquired BRAF inhibitor resistance due to PDGFRα upregulation [166].”
BackgroundIn–Situ‐Sprayed Dual‐Functional Immunotherapeutic Gel for Colorectal Cancer Postsurgical Treatment
Si, X., Ji, G., Ma, S., Xu, Y., Zhao, J., Zhang, Y., Huang, Z., Tang, Z., Song, W., & Chen, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100862 · Cited by 43
Eveno, C., Karoui, M., Gayat, É., Luciani, A., Auriault, M., Kluger, M. D., Baumgaertner, I., Baranès, L., Laurent, A., Tayar, C., et al. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00581.x · Cited by 43
Scartozzi, M., Giampieri, R., Maccaroni, E., Mandolesi, A., Giustini, L., Silva, R., Zaniboni, A., Biscotti, T., Biagetti, S., Galizia, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr558 · Cited by 43
“K-RAS wild type) [1–3].”
Clinical Application of Genetics in Management of Colorectal Cancer
Kim, E. R., & Kim, Y.-H. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.3.184 · Cited by 43
Étienne-Grimaldi, M.-C., Bennouna, J., Formento, J., Douillard, J.-Y., Francoual, M., Hennebelle, I., Chatelut, É., François, É., Faroux, R., Elhannani, C., et al. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04141.x · Cited by 43
Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer
Takahashi, H., Ishikawa, T., Ishiguro, M., Okazaki, S., Mogushi, K., Kobayashi, H., Iida, S., Mizushima, H., Tanaka, H., Uetake, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1783-y · Cited by 42
Kim, J. C., Kim, S., Cho, D. H., Ha, Y. J., Choi, E. Y., Kim, C. W., Roh, S. A., Kim, T. W. B., Ju, H., & Kim, Y. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1907 · Cited by 46
Warburg effect regulated by amphiregulin in the development of colorectal cancer
Nam, S. O., Yotsumoto, F., Miyata, K., Fukagawa, S., Yamada, H., Kuroki, M., & Miyamoto, S. (2015) · Cancer Medicine · doi:10.1002/cam4.416 · Cited by 41
“Various molecular targeted agents such as anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab) and anti-epidermal growth factor receptor (EGFR) monoclonal antibody (cetuximab) have been developed for CRC therapy [2, 3].”
BackgroundMolecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
“9 months in the subgroup of patients with KRAS wild-type tumors who received the MoAb.(7) The PRIME trial evaluated the addition of panitumumab to FOLFOX, and PFS increased from 8 to 9.”
BackgroundResultInfluentialPharmacogenomics in oncology care
Filipski, K. K., Mechanic, L. E., Long, R. M., & Freedman, A. N. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00073 · Cited by 52
Cushman-Vokoun, A. M., Stover, D. G., Zhao, Z., Koehler, E. A., Berlin, J. D., & Vnencak-Jones, C. L. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.005 · Cited by 24
Guinney, J., Ferté, C., Dry, J., McEwen, R., Manceau, G., Kao, K., Chang, K.-M., Bendtsen, C., Hudson, K., Huang, E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1943 · Cited by 43
Maker, A. V., Ito, H., Mo, Q., Weisenberg, E., Qin, L., Turcotte, S., Maithel, S. K., Shia, J., Blumgart, L. H., Fong, Y., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0212 · Cited by 42
A statistician's perspective on biomarkers in drug development
Jenkins, M. A., Flynn, A. A., Smart, T. S., Harbron, C. G., Sabin, T., Ratnayake, J., Delmar, P., Herath, A., Jarvis, P., Matcham, J., et al. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.532 · Cited by 46
“In comparison, if the biomarker were predictive of response to the investigative treatment, as for K-ras wild type in colorectal cancer patients treated with cetuximab [6], then the biomarker-defined group (in this case those without a mutation) demonstrate a larger treatment effect than other patients.”
BackgroundDasari, A. N., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2283 · Cited by 48
“The CRYSTAL trial (540 out of 1,198 tested for KRAS mutation) evaluated FOLFIRI ± cetuximab, and the OPUS trial (233 out of 337 tested for KRAS mutation) evaluated FOLFOX ± cetuximab (12, 13).”
MethodJeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 49
Mori, Y., Nyuya, A., Yasui, K., Toshima, T., Kawai, T., Taniguchi, F., Kimura, K., Inada, R., Nishizaki, M., Haraga, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24735 · Cited by 42
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 51
“No improvement in OS has been reported in this study, similarly to the previously mentioned trial [99].”
ResultThe inhibitory effects of 5‐hydroxy‐3,6,7,8,3′,4′‐hexamethoxyflavone on human colon cancer cells
Qiu, P., Guan, H., Dong, P., Guo, S., Zheng, J., Li, S., Chen, Y., Ho, C., Pan, M., McClements, D. J., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100070 · Cited by 43
“Compelling evidence has suggested that mutations in K-Ras can lead to resistance to anti-EGFR treatments because K-Ras acts downstream of EGFR [10–17].”
BackgroundWu, S., Gan, Y., Wang, X., Liu, J., Li, M., & Tang, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1400-x · Cited by 44
Kobayashi, T., Teruya, M., Kishiki, T., Endo, D., Takenaka, Y., Miki, K., Kobayashi, K., & Morita, K. (2010) · Digestive Surgery · doi:10.1159/000280021 · Cited by 42
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 46
Richiardone, E., Roumi, R. A., Lardinois, F., Giolito, M. V., Ambroise, J., Boidot, R., Drotleff, B., Ghesquière, B., Bellahcène, A., Bardelli, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217091 · Cited by 43
Butzke, B., Oduncu, F. S., Severin, F., Pfeufer, A., Heinemann, V., Gießen-Jung, C., Stollenwerk, B., & Rogowski, W. H. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1053983 · Cited by 41
Mitchell, E. P., Piperdi, B., Lacouture, M. E., Shearer, H., Iannotti, N. O., Pillai, M. V., Xu, F., & Yassine, M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.004 · Cited by 44
DNA Testing and Molecular Screening for Colon Cancer
Carethers, J. M. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.12.007 · Cited by 41
“This mutational activation, now independent from the effects of EGFR, make cetuximab and panitumab ineffective due to incessant downstream signaling below EGFR even when EGFR is inhibited (26).”
Devaud, N. A., Kanji, Z. S., Dhani, N. C., Grant, R. C., Shoushtari, H., Serrano, P. E., Nanji, S. A., Greig, P. D., McGilvray, I. D., Moulton, C.-A., et al. (2013) · HPB · doi:10.1111/hpb.12159 · Cited by 41
Lin, A. Y., Buckley, N. S., Lu, A.-T. T., Kouzminova, N. B., & Salpeter, S. R. (2011) · Clinical Colorectal Cancer · doi:10.3816/ccc.2011.n.009 · Cited by 49
Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions
Rousseau, B., Chibaudel, B., Bachet, J., Larsen, A. K., Tournigand, C., Louvet, C., André, T., & de Gramont, A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ddc5bf · Cited by 43
Clinical cancer genomics: how soon is now?
Taylor, B. S., & Ladanyi, M. (2010) · The Journal of Pathology · doi:10.1002/path.2794 · Cited by 43
Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Reboredo, M., Manzano, J. L., Rivera, F., Safont7, M., Montagut, C. O., González‐Flores, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047345 · Cited by 43
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
“[4,58] In clinical trials, no benefit from these antibodies was observed if the KRAS exon 2 (codon 12 and 13) was mutated.[59,60] Expanded analysis showed that mutations in KRAS exons 3 and 4 as well as NRAS exons 1, 2, 3 and 4 abolished any benefit from cetuximab [61] or panitumumab.”
BackgroundResultBouché, O., Maindrault‐Gœbel, F., Ducreux, M. P., Lledo, G., André, T., Stopfer, P., Amellal, N., Merger, M., & de Gramont, A. (2011) · PubMed · Cited by 44
Gleeson, F. C., Kipp, B. R., Voss, J. S., Campion, M. B., Minot, D. M., Tu, Z. J., Klee, E. W., Sciallis, A. P., Graham, R. P., Lazaridis, K. N., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpu3j7fgayqbrl · Cited by 42
“20-22 The aims of this targeted NGS-based translational study were to evaluate EUS FNA cytology specimens obtained from malignant lymph nodes (LNs) in patients with sporadic, treatment-naïve, locally advanced rectal cancer to determine the (1) frequency of LN pathogenic alterations; (2) presence of one or more alterat…”
BackgroundAprile, G., Rihawi, K., Carlo, E. D., & Sonis, S. T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i41.11793 · Cited by 48
Shao, Y., Hsu, C.-H., & Cheng, A.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10336 · Cited by 44
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Iida, M., Bahrar, H., Brand, T. M., Pearson, H. E., Coan, J. P., Orbuch, R. A., Flanigan, B. G., Swick, A. D., Prabakaran, P. J., Lantto, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0012 · Cited by 43
LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases
Qiao, G., Qin, J., Kunda, N. M., Calata, J. F., Mahmud, D. L., Gann, P. H., Fu, Y., Rosenberg, S. A., Prabhakar, B. S., & Maker, A. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1655 · Cited by 43
Mutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 43
A novel treatment for metastatic lymph nodes using lymphatic delivery and photothermal therapy
Oladipo, A. O., Oluwafemi, O. S., Songca, S. P., Sukhbaatar, A., Mori, S., Okajima, J., Komiya, A., Maruyama, S., & Kodama, T. (2017) · Scientific Reports · doi:10.1038/srep45459 · Cited by 44
Carotenuto, P., Roma, C., Rachiglio, A. M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, V., Botti, G., & Normanno, N. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.86 · Cited by 41
Germination Improves the Polyphenolic Profile and Functional Value of Mung Bean (Vigna radiata L.)
Kapravelou, G., Martínez, R., Perazzoli, G., Sánchez‐González, C., Llopis, J., Cantarero, S., Goua, M., Bermano, G., Prados, J. C., Melguizo, C., et al. (2020) · Antioxidants · doi:10.3390/antiox9080746 · Cited by 41
“This added to a survival rate of 10% after 5 years [5], and a limited treatment success with surgery or with 5-fluorouracil (5FU) combined with other agents, such as irinotecan, capecitabine or oxaliplatin, and monoclonal antibodies such as cetuximab and bevacizumab [6], emphasize the need to develop new effective str…”
BackgroundComprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancer
Kondo, T., Matsubara, J., Quy, P. N., Fukuyama, K., Nomura, M., Funakoshi, T., Doi, K., Sakamori, Y., Yoshioka, M., Yokoyama, A., et al. (2020) · Cancer Science · doi:10.1111/cas.14674 · Cited by 41
Guin, S., Yao, H., & Wang, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900168v · Cited by 41
Ferreira, C. G., Aran, V., Zalcberg-Renault, I., Victorino, A. P., Salem, J. H., Bonamino, M., Vieira, F. M. D. A. C., & Zalis, M. G. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-73 · Cited by 44
“Clinically, patients with KRAS wild-type tumours are more likely to respond to anti-EGFR therapy whereas those with mutant KRAS show lack of benefit [9-14].”
BackgroundNovel Immunotherapeutic Strategies of Gastric Cancer Treatment
Amedei, A., Benagiano, M., Bella, C. D., Niccolai, E., & D’Elios, M. M. (2011) · BioMed Research International · doi:10.1155/2011/437348 · Cited by 44
EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
Grothey, A. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3407 · Cited by 47
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
Bertolini, F., Malavasi, N., Scarabelli, L., Fiocchi, F., Bagni, B., Giovane, C. D., Colucci, G., Gerunda, G. E., Depenni, R., Zironi, S., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.43 · Cited by 40
“…with a response rate of 34–80% and a resectability rate of 2–92% (depending on patient selection) (Tournigand et al, 2004; Falcone et al, 2007; Gruenberger et al, 2008; Bokemeyer et al, 2009; Okines et al, 2009; Van Cutsem et al, 2009; Wong et al, 2009; Folprecht et al 2010; Masi et al, 2010).”
BackgroundManzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 47
The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence
Maspero, M., Yılmaz, S., Cazzaniga, B., Raj, R., Ali, K., Mazzaferro, V., & Schlegel, A. A. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100846 · Cited by 53
“Cetuximab and panitumumab are anti-EGFR monoclonal antibodies used in metastatic CRC either in combination with chemotherapy or as monotherapy.(122,123) HGF is a major driver of hepatocyte proliferation during liver regeneration.”
BackgroundUnveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 46
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 49
Schmiegel, W., Pox, C. P., Arnold, D., Porschen, R., Rödel, C. M., & Reinacher‐Schick, A. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0843 · Cited by 40
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.